03 nov: OMXS30 Weekly Options Expiration Value 78/17
03 nov: Share repurchase programme
03-11-2017 09:26:27

ALK appoints Søren Jelert as new Chief Financial Officer

Relateret indhold
10 nov - 
Fredagens aktier: C20 i rødt efter fortsat nedtur for V..
10 nov - 
Aktier/middag: Vestas, Mærsk og Pandora trækker C20 i r..
10 nov - 
ALK Q3: Husstøvmidetablet nærmer sig markedet i USA - N..
Relateret debat
11 nov - 
Lad nu den bolle få et engelskkursus. Det er måske det ..
10 nov - 
Suppleret lidt op med 28 stk til 929 til nu 168 her til..
10 nov - 
Tallene er ikke specielt skuffende, men nogenlunde på l..

 

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced the appointment of Søren Jelert as its new Chief Financial Officer (CFO) and Executive Vice President.

 

From 2008 until 2016, Søren Jelert, who is 45, was CFO at NNE, an engineering company that specialises in supporting pharmaceutical company engineering projects. Since 2016, he has been General Manager of NNE's US organisation. His career has also included various finance roles at Novo Nordisk and Maersk. 

 

Carsten Hellmann, ALK’s President and CEO, said: “Søren Jelert brings a wealth of experience to ALK, in particular, from his previous pharmaceutical industry-focused roles at NNE and Novo Nordisk. He has a proven track record of financial leadership and he has also played a pivotal role in transformation processes that are comparable to the one we are embarking upon at ALK.”

 

Søren will be based at ALK’s headquarters in Hørsholm, Denmark and will report directly to Carsten Hellmann. He is expected to take up his new role by 2 January 2018.

 

Søren commented: "This new role offers me the opportunity to use my knowledge and experience to support and further develop ALK as it works to build a new growth platform and to become a truly global allergy company."

 

Søren Jelert succeeds Flemming Pedersen, whose decision to leave ALK was announced in July 2017.  

 

ALK-Abelló A/S

 

For further information please contact:

Carsten Hellmann, President & CEO, tel. +45 4574 7576

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Media: Jeppe Ilkjær, tel. +45 7877 4532, mobile +45 3050 2014

 

This information is information that ALK-Abelló A/S is obliged to make public pursuant to the EU Market Abuse Regulation.

 

About ALK

ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy – a treatment of the underlying cause of allergy. The company has approximately 2,300 employees, with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Torii, Abbott, and Seqirus to commercialise sublingual allergy immunotherapy tablets in Japan, Russia, and South-East Asia, and Australia and New Zealand, respectively. The company is headquartered in Hørsholm, Denmark, and listed on Nasdaq Copenhagen. Find more information at www.alk.net.

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/67095a20-1bd8-4156-9150-23d9b618a49d

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Vestas/Sydbank: Vindmølleindustrien risikerer endnu lavere priser

22-11-2017 14:28:26
Priserne på vindmøller har været nedadgående de seneste måneder, og Vestas og de andre aktører i branchen skal ikke forvente, at det værste er overstået.Det vurderer aktieanalytiker Jacob Pedersen fra Sydbank, efter at den seneste store vindauktion i Tyskland blev afgjort med prisfald på 11 pct.- Priserne matcher meget godt den udvikling, vi har set og hørt om fra vindmølleproducenterne, så hvis m..

Novo/dir: Vækst i biofarma er afhængig af tilkøb

22-11-2017 10:07:28
Novo Nordisks ambition om at vende den negative udvikling for selskabets biofarmaforretning, så den atter kan begynde at vokse frem mod 2020, er afhængig af tre dele, herunder opkøb.Det fortalte direktør for Novos bløderdivision, Christian Kanstrup, tirsdag på Novos kapitalmarkedsdag.Salget af Novos blødermiddel Novoseven er under pres fra det konkurrerende blødermiddel Hemlimbra fra Roche, som No..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Genmab, Vestas og Pandora fortsat i fokus
2
Vestas får første russiske ordre nogensinde - NY
3
Vestas/CS: Prisudvikling og arbejdskapital koster på kursmålet - NY
4
Onsdagens aktier: Kapitalfonds retræte trak Pandora til tops
5
Vestas: Ny tysk vindauktion understreger stort prispres

Relaterede aktiekurser

ALK-Abelló B A/S 912,50 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
23. november 2017 04:18:39
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171108.1 - EUROWEB2 - 2017-11-23 04:18:39 - 2017-11-23 04:18:39 - 1 - Website: OKAY